Clinical Study

Avb500-Oc-004 A Phase 3, Randomized, Double-Blind, Adaptive, Placebo/Paclitaxel-Controlled Study Of Avb-S6-500 In Combination With Paclitaxel In Patients With Platinum-Resistant Recurrent Ovarian Cancer

Posted Date: Aug 3, 2021

  • Investigator: Thomas Herzog
  • Specialties: Gynecologic Oncology, Oncology, Ovarian Cancer
  • Type of Study: Drug

The purpose of this study will be to compare efficacy and tolerability of AVB-S6-500 in combination with paclitaxel (Pac) versus placebo versus Pac. This is a Phase 3 study of AVB-S6-500 in combination with Pac in patients with platinum resistant recurrent ovarian cancer. Efficacy will be determined by looking at anti-tumor activity of AVB-S6-500 in combination with Pac measured by progression free survival in patients receiving AVB-S6-500+ Pac versus patients receiving Placebo+Pac.


Only Patients With High-Grade Serous Adenocarcinoma Histology Are Eligible. Eastern Cooperative Oncology Group Performance Status (Ecog-Ps) Of 0 To 1. Patient Must Have Received At Least 1 But Not More Than 4 Prior Therapy Regimens. Patient Must Have Measurable Disease According To Recist V1.1 Criteria. No Tumors In The Breast Or Bone. No Untreated Central Nervous System (Cns) Metastases.No Primary Platinum-Refractory Disease. No Patient That Is Being Treated With Concurrent Anticancer Therapy Or Other Interventional Treatments Administered For Their Underlying Ovarian Cancer.


Phase 3, Ovarian, Gyn Onc

For More Information:

Uc Cancer Center

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.